Mitochondrial Myopathy Diagnosis & Treatment Market to Gain Momentum at 9.82% CAGR to 2020

05 Feb 2018 • by Natalie Aster
Mitochondrial Myopathy Diagnosis & Treatment Market to Gain Momentum at 9.82% CAGR to 2020

LONDON – Mitochondrial myopathies (MM) represent a group of conditions affecting the mitochondria, the tiny energy producing structures found inside practically all cells. The term refers to a group of muscle disorders, including Kearns-Sayre syndrome, Pearson syndrome, mitochondrial encephalomyopathy, Leigh’s syndrome, etc. It is a rare mutational disease, and there are currently no clear-cut therapies available in the market for the disease. However, there are a number of tests helping confirm a diagnosis of MM available in the marketplace, which are the only saving grace for the world MM diagnosis and treatment market to date.

Globally, the MM diagnosis and treatment market is projected to record a 9.82% CAGR to be worth USD 33.6 million by 2020. The key factors responsible for the market growth includes an upsurge in the number of incidence rates of MM alongside the mushrooming volume of screening services, as well as the government investment in, and initiatives pertaining to rare genetic disorders. However, inadequate treatment modalities and dearth of curative treatment, and insufficient awareness and diagnosis of the rare mitochondrial diseases are amid the factors that could limit the market growth.

Top Segments of MM Diagnosis & Treatment Market

The mitochondrial encephalomyopathy, lactic acidosis, and stroke segment (MELAS) captured the biggest chunk (17.1%) of the market as of 2016. The sector is poised to gather momentum at a 10.08% CAGR to be valued at USD 5.8 million by end-2020.

Based on diagnostic test, the genetic test segment is poised accounted for the dominant share of close to 75% of the market in 2016. This sector is expected to reach a value of USD 25.6 million in 2020, registering a 10.11% CAGR over the forecast period.

The supportive therapy segment was an unbeatable leader grabbing a market share of 100% as of 2016. In the years to come, the targeted therapy is set to be the 2nd-largest market, which is expected to grow at a 9.82% CAGR through to 2020.

Americas Take Lead in Global MM Diagnosis & Treatment Market

The Americas region commanded the largest share (44%) of the market in 2016, and the regional market is projected to reach USD 15 million in 2020 demonstrating a 10.8% CAGR in the offing.

For more insightful information pertaining to the mitochondrial myopathy diagnosis & treatment market go to this page at MarketPublishers.com.

CONTACTS

The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970
ps@marketpublishers.com
MarketPublishers.com